Immunohistochemical Assessment of PD-L1 in HCC

PD-L1 expression was measured by immunohistochemistry pharmDx assay (Agilent Technologies, Santa Clara, CA, USA) on archive HCC tissues for 18 patients. The anti-PD-L1 28-8 antibody was used for nivolumab-treated HCC, and anti-PD-L1 22C3 antibody was applied for pembrolizumab-treated HCC [7 (link),8 (link)]. Expression levels were reported by tumor proportion score (TPS) and/or combined positive score (CPS), respectively [7 (link),8 (link)].

Free full text: Click here

Lee P.C., Chao Y., Chen M.H., Lan K.H., Lee C.J., Lee I.C., Chen S.C., Hou M.C, & Huang Y.H. (2020). Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers, 12(1), 182.

Publication 2020

pharmDx assay

Anti antibody Assay Immunohistochemistry Nivolumab Patients Pd l1 Pembrolizumab Tissues Tumor

Corresponding Organization :

Other organizations : National Yang Ming Chiao Tung University, Taipei Veterans General Hospital

Top 5 similar protocols

Protocol cited in 1 other protocol

Variable analysis

independent variables

Anti-PD-L1 28-8 antibody
Anti-PD-L1 22C3 antibody

dependent variables

PD-L1 expression levels reported by tumor proportion score (TPS)
PD-L1 expression levels reported by combined positive score (CPS)

control variables

HCC tissue samples from 18 patients

controls

No positive or negative controls were explicitly mentioned.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!